Health Care · Services-Offices & Clinics of Doctors of Medicine

HIMS Hims & Hers Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1773751169 filings
Russell 2000

HIMS at a glance

Hims & Hers Health, Inc. (HIMS, SEC CIK 1773751) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Hims & Hers Health, Inc. (HIMS) reported revenue of $2.3 billion (up 59.0% from FY2024) and net income of $128.4 million. Diluted EPS was $0.51.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Hims & Hers Health, Inc. (HIMS) shares worth $2.7 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Okupe Oluyemi on November 17, 2026 of 3,518 shares at $18.53 per share.
  • In the last 90 days, HIMS insiders reported 0 open-market purchases ($0) and 13 open-market sales ($3.1M) on Form 4, a net sale of $3.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.3B
+59.0% vs prior year
Insiders · 90 days
0 buys · 13 sells
Net −$3.1M
13F holders
36 funds
$2.7B · +1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Consumer-first digital health platform offering telehealth consultations, personalized prescription and non-prescription products, and laboratory testing
  • New 2025 offerings: Testosterone, menopause, perimenopause support, and comprehensive laboratory testing for early health risk identification
  • Strategic shift: Accelerated international expansion including pending acquisition of Australia-based Zava, enhancing global footprint across 5 countries
  • Quantitative note: Over 50 million telehealth consultations facilitated since founding, with extended operations in US, UK, Canada, EU (Germany, Ireland, France, Spain)
  • Noteworthy fact: Integrated ownership of 4 pharmacies and specialty facilities (compounding, peptide manufacturing, lab), reducing costs and improving operational control

Risk Factors

  • Cybersecurity risks reviewed quarterly by Audit Committee with escalation to CTO and executive leadership
  • Head of Information Security with 20 years experience, certified CISSP, CCSP, CRISC, CCISO, reporting to CTO
  • Dedicated cybersecurity team with industry-recognized credentials maintaining current professional education

Management Discussion & Analysis

  • Revenue $2.35B in 2025, up 59% YoY from $1.48B in 2024, driven by U.S. Revenue growth $2.21B (+53%) and Rest of World Revenue $134M (+399%)
  • Online Revenue $2.31B in 2025, up 61% YoY from $1.44B; Wholesale Revenue $36.2M down 6% YoY from $38.6M
  • Subscribers 2.51M in 2025, up 13% YoY from 2.23M; Monthly Revenue per Average Subscriber $83 (+28%) vs $65
  • Operating investments in facilities, marketing, product development; recent acquisitions including Zava (July 2025) and Medici (Nov 2025)
  • Forward outlook: 2026 acquisition of Eucalyptus ($1.15B total consideration) to expand international presence; expect continued growth but risks from marketing effectiveness, regulatory changes, and macroeconomic factors

AI summary of the HIMS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $890.4M, up 49% YoY from $599.0M, driven by Rest of World revenue $233.3M, up 321%
  • Gross margin 57% vs 74% YoY; net loss $33.0M vs net income $15.8M
  • Hers strongest growth driver, 45% of U.S. revenue, versus approximately 40% YoY
  • Operating cash flow $65.4M vs $148.7M YoY; free cash flow $26.0M vs $79.4M
  • Near-term headwinds: gross margin below comparative periods from weight loss offerings, international acquisitions, and shorter shipping cadences

Risk Factors

  • New regulatory risk: testosterone therapy launched in 2026, with Schedule III products subject to DEA registration and controlled-substance requirements
  • Most material update: FDA directly named Hims & Hers in February 2026 GLP-1 statement, while HHS referred the company to DOJ
  • Legal exposure: FTC and state plaintiffs filed a July 2026 ROSCA and FTC Act complaint, with approximately $60 million accrued
  • Operational risk: branded GLP-1 transition may reduce demand and increase churn among customers using compounded alternatives
  • Financial risk: branded GLP-1 procurement costs may pressure margins, with limited ability to pass through price increases

AI summary of the HIMS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Full operating and financial details contained in Exhibit 99.1 press release

Item 8.01: Other Events

  • Hims & Hers identifies websites, SEC filings, calls, blogs and social media as potential channels for material disclosures
  • Investors should monitor the company’s investor relations and news websites for timely updates

Item EX-99.1: Item EX-99.1

  • Q3 revenue $890.4M, up 49% year-over-year, with subscribers up 13% to 2.788M
  • Revenue per average subscriber $105, up 30%, indicating monetization outpaced subscriber growth
Filed Nov 9, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Andrew Huberman appointed as tenth director, effective November 4, 2026, but does not qualify as NYSE-independent
  • Board role paired with two-year advisory agreement, $3.5M annual cash fee plus up to $1M annually for paid advertising videos
Filed Oct 7, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jonathan M. Franklin appointed principal accounting officer effective October 9, 2026, replacing Irene Becklund
  • Becklund remains available under an advisory agreement through July 10, 2027, supporting transition continuity

AI summaries of HIMS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for HIMS

Don't miss the next HIMS filing

  • Alerts as it files. A push when HIMS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut HIMS, by share count.
  • Ask anything. An AI agent that reads every HIMS filing and answers with sources.

HIMS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Okupe OluyemiSellNov 17, 2026$18.53
Boughton SoleilSellNov 17, 2026$18.53
Autor Deborah M.SellNov 17, 2026$18.53
Dudum AndrewMNov 13, 2026-
Elshenawy MohamedMNov 13, 2026-
Elshenawy MohamedFNov 13, 2026$19.73
Dudum AndrewFNov 13, 2026$19.73
Elshenawy MohamedMNov 13, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$872.0M$1.5B$2.3B
Gross Profit$714.9M$1.2B$1.7B
Operating Income-$61.9M$105.6M
Net Income-$23.5M$126.0M$128.4M
Gross Margin82.0%79.5%73.8%
Op. Margin-4.2%4.5%
Net Margin-2.7%8.5%5.5%
Balance Sheet
Total Assets-$707.5M$2.2B
Equity-$476.7M$540.9M
ROE-26.4%23.7%
Per Share
EPS$-0.11$0.53$0.51
Cash Flow
Operating CF-$251.1M$300.0M

Source: XBRL data in Hims & Hers Health, Inc. (HIMS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate HIMS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
HIMS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$2.69B
Q2 202635$3.23B
Q1 202632$1.84B
Q4 202532$4.16B
Q3 202535$8.82B
Q2 202535$5.25B
Q1 202531$2.35B
Q4 202425$1.40B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 261 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

HIMS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
8-KNov 9, 2026Analysis-
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Oct 29, 2026--
4Oct 15, 2026--
8-KOct 7, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Sep 23, 2026--

Related Health Care companies

All Health Care →

HIMS SEC filings: frequently asked questions

Are HIMS insiders buying or selling?

In the last 90 days, Hims & Hers Health, Inc. (HIMS) officers, directors and 10% owners reported no open-market purchases and 13 open-market sales worth $3.1 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold HIMS stock?

As of September 30, 2026, the largest Hims & Hers Health, Inc. (HIMS) holders among the 13F filers tracked by SignalX were BlackRock ($885.9 million), Vanguard Portfolio Management LLC ($310.1 million), Vanguard Capital Management LLC ($283.8 million), State Street Corp ($245.5 million), Morgan Stanley ($185.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was HIMS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Hims & Hers Health, Inc. (HIMS) reported revenue of $2.3 billion (up 59.0% from FY2024) and net income of $128.4 million. Diluted EPS was $0.51. The figures come from the XBRL data in the 10-K.

What are the main risks in HIMS's latest 10-K?

In the 10-K filed February 23, 2026, Hims & Hers Health, Inc. (HIMS) flagged: Cybersecurity risks reviewed quarterly by Audit Committee with escalation to CTO and executive leadership. Head of Information Security with 20 years experience, certified CISSP, CCSP, CRISC, CCISO, reporting to CTO. (AI summary of the Risk Factors section.)

What did HIMS report in its latest 8-K?

Hims & Hers Health, Inc. (HIMS) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Q3 2026 results announced for quarter ended September 30, 2026.

What are the latest HIMS SEC filings?

Hims & Hers Health, Inc. (HIMS) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 18, 2026.

What is HIMS's SEC CIK number?

Hims & Hers Health, Inc. (HIMS)'s SEC Central Index Key (CIK) is 1773751. EDGAR lists every HIMS filing under that number.

Ask anything about HIMS

The research agent reads HIMS's filings, financials, insider trades and 13F holders, then answers with sources.